Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is one of the penny stocks with the potential to rise 1000 percent. On March 27, Rocket Pharmaceuticals said the FDA approved KRESLADI for a rare pediatric disorder, giving the company its first marketed product and a key regulatory win after a long review path. The company said the approval also makes KRESLADI the first FDA-approved gene therapy for this condition, which gives Rocket a commercial foothold in an ultra-rare disease market. The bigger takeaway is ...